A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.
from Medical Xpress - latest medical and health news stories https://ift.tt/62vSEbm
